Arbutus Biopharma | Investor Presentation Deck

The slide uses a map to show regional prevalence and a nested circle diagram to show the funnel from total infected to diagnosed to treated.diagnose_problem

Open slide detailBeat · ProblemLoop · Cost Of Inaction

The slide uses a process-flow diagram to show how different mechanisms of action (NA, RNAi, PD-L1 Inhibitor, Interferon, Vaccines) contribute to the three pillapresent_solution

Open slide detailBeat · SolutionLoop · Cost Of Inaction

transition

Open slide detailLoop · Cost Of Inaction

The slide uses a bulleted list to summarize the therapeutic profile and a diagram to illustrate the mechanism of action targeting HBV transcripts.present_solution

Open slide detailBeat · ProductLoop · Cost Of Inaction

The slide outlines trial design cohorts (E, F, G, I, J, K) and summarizes findings from parts 1 & 2.present_framework

Open slide detailLoop · Cost Of Inaction

The table displays mean (SE) log10 IU/mL values for various cohorts (E, F, I, J, K, G) from baseline through follow-up week 48.analyze_data

Open slide detailLoop · Cost Of Inaction

The slide displays longitudinal data for cohorts E, F, I, J, G, and K, highlighting individual subject responses.analyze_data

Open slide detailLoop · Cost Of Inaction

The slide displays 8 individual patient charts tracking biomarker levels over time, with specific annotations for NA retreatment.analyze_data

Open slide detailLoop · Cost Of Inaction

Data presented at EASL 2022. Shows longitudinal patient data for patients 42, 43, and 48.analyze_data

Open slide detailLoop · Cost Of Inaction

The slide uses a bulleted list format to present key safety findings.summarize

Open slide detail

summarize

Open slide detail

The slide uses a timeline-based process diagram to illustrate the randomization and treatment arms of the clinical trial.present_solution

Open slide detail

The slide outlines two distinct treatment arms involving Imdusiran, VTP-300, and Nivolumab.present_framework

Open slide detail

The slide details a specific licensing deal with Qilu Pharmaceutical.present_solution

Open slide detail

transition

Open slide detail

The slide uses a three-column layout to explain the scientific basis and therapeutic advantages of the drug candidate.present_solution

Open slide detail

The slide shows two distinct experiments: an in vitro T-cell activation assay and an in vivo tumor reduction study.analyze_data